Significance of serological atrophic gastritis on proton pump inhibitor prescriptions and referrals to gastroscopy in the general population.

BACKGROUND AND AIM

We aimed to investigate whether individuals with low pepsinogen I levels differed from those with normal pepsinogen I levels in terms of proton pump inhibitors (PPIs) use, referral to gastroscopy, and findings on gastroscopy.

METHODS

Serum pepsinogen I was measured in 518 persons (mean age 51.6, SD 8.8; 49% women). A medical chart review focused on PPI prescriptions and gastroscopic findings in the follow-up period.

RESULTS

Patients with serological atrophic gastritis (pepsinogen I < 28 μg/L) had higher body mass index (27.5 26.2 kg/m;  = 0.007), were less likely to be current smokers (8% 17%;  = 0.025), and had higher prevalence of seropositivity (57% 36%;  < 0.001) compared with those without. During follow-up (mean 21.4 years, SD 6.5 years), the patients with serological atrophic gastritis had more often findings of atrophic gastritis or gastric polyps on gastroscopy (20% 8%;  < 0.001), despite no differences in the mean number of gastroscopies per 1000 person-years (33 23;  = 0.19) and the mean prescribed PPI dose (omeprazole equivalents) per year (1064 mg 1046 mg;  = 0.95). Persons with serological atrophic gastritis had lower odds of being prescribed PPIs at least once (odds ratio [95% confidence interval]: 0.58 [0.35-0.96]), but there was no significant difference in the chance of being referred to gastroscopy at least once (1.15 [0.70-1.96]).

CONCLUSION

Persons with serological atrophic gastritis were less likely to be prescribed PPIs. Persons with serological atrophic gastritis had more often gastric polyps and atrophic gastritis when referred to gastroscopy.